Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1

Journal of Pharmaceutical Sciences

Volumn 97, Issue 10, 2008, Pages 4228-4239

  Gupta, Kavita M ^a   Pearce, Serena M ^a   Poursaid, Azadeh E ^a   Aliyar, Hyder A ^a   Tresco, Patrick A ^a   Mitchnik, Mark A ^b   Kiser, Patrick F ^a,c  

^a Department of Electrical and Computer Engineering   (United States)

^b Particle Sciences Inc   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Controlled delivery; Dapivirine; Diffusion; Formulation vehicle; Intravaginal ring; Long duration microbicide; Nonnucleoside reverse transcriptase inhibitor; Polymeric drug carrier; Release kinetics

Indexed keywords

DAPIVIRINE; LIPOSOME; POLYURETHAN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TECOFLEX EG 80A; UNCLASSIFIED DRUG;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; PROPHYLAXIS; SEXUAL TRANSMISSION; SUSTAINED DRUG RELEASE; THERMOSTABILITY; VAGINA RING;

EID: 54849431632     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21331     Document Type: Article

References (50)

1. UNAIDS/WHO. 2006. AIDS Epidemic Update. Geneva, Switzerland: UNAIDS.
2. Glynn JR, Carael M, Auvert B, Kahindo M, Chege J, Musonda R, Kaona F, Buve A. 2001. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. AIDS 15:S51-S60.
3. Stone A. 2002. Microbicides: A new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 1:1977-1985.
4. Watts C, Vickerman P. 2001. The impact of microbicides on HIV and STD transmission: Model projections. AIDS 15:S43-S44.
5. Peterson L, Toxler A, Belai G. Microbicides 2006. South Africa: Cape Town. 2006. pp OD13.
6. Woolfson AD, Malcolm RK, Toner CF, Morrow RJ, Lowry D, Jamil A, McCullagh SD. 2006. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: A controlled-release strategy for HIV microbicides. Am J Drug Delivery 4:7-20.
7. Faundes A, Brache V, Alvarez F. 2004. Pros and cons of vaginal rings for contraceptive hormone delivery. Am J Drug Delivery 2:241-250.
8. Roumen F. 2002. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care 7:19-24; discussion 37-19.
9. Sarkar NN. 2005. The combined contraceptive vaginal device (NuvaRing): A comprehensive review. Eur J Contraception Reprod Health Care 10:73-78.
10. Malcolm K, Woolfson D, Russell J, Andrews C. 2003. In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. J Control Release 91:355-364.
11. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. 2005. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 56:954-956.
12. Han YA, Singh M, Saxena BB. 2007. Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. Contraception 76:132-138.
13. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. 2006. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 325:82-89.
14. D'Cruz OJ, Uckun FM. 2006. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 57:411-423.
15. Dezarnaulds G, Fraser IS. 2003. Vaginal ring delivery of hormone replacement therapy - A review. Expert Opin Pharmacother 4:201-212.
16. Ballagh SA. 2001. Vaginal ring hormone delivery systems in contraception and menopause. Clin Obstet Gynecol 44:106-113.
17. Oddsson K, Leifels-Fischer B, Wiel-Masson D, de Melo NR, Benedetto C, Verhoeven CH, Dieben TO. 2005. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: A randomized trial. Hum Reprod 20:557-562.
18. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. 2006. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 325:82-89.
19. Frenkel YV, Clark AD, Jr., Das K, Wang YH, Lewi PJ, Janssen PA, Arnold E. 2005. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J Med Chem 48:1974-1983.
20. Das K, Clark AD, Jr., Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E. 2004. Roles of conformational and positional adaptability in structurebased design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47:2550-2560.
21. Motakis D, Parniak MA. 2002. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46:1851-1856.
22. Romano J, Coplan P, Mitchnick M, Douville K, Malcolm K, Van Roey J, Temmerman M, Van Bortel L, Weyers S, Rosenberg Z. 2006. AIDS 2006 - XVI International AIDS Conference, Toronto, pp Abstract no. WEA A0503.
23. Romano J, Variano B, Coplan P, Roey JV, douville K, Rosenberg Z, Temmerman M, Van Bortel L, Weyers S, Mitchnick M. 2007. Sustained Delivery of the Microbicide Dapivirine Using Intra-vaginal Rings: Independent Clinical Assessments of Drug Delivery and Safety in Women. 14th Conference on Retrovirus and Opportunistic Infections ed., Los Angeles, USA.
24. Higuchi T. 1963. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145-1149.
25. Weisberg E, Fraser IS, Baker J, Archer D, Landgren BM, Killick S, Soutter P, Krause T, d'Arcangues C. 2000. A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. Contraception 62:83-89.
26. Demetrio CG, Ridout MS. 1994. Coping with extra Poisson variability in the analysis of factors influencing vaginal ring expulsions. Stat Med 13:873-876.
27. Campbell MJ, Machin D, D'Arcangues C. 1991. Coping with extra Poisson variability in the analysis of factors influencing vaginal ring expulsions. Stat Med 10:241-254.
28. Mishell DR, Jr., Colodny SZ, Swanson LA. 1969. The effect of an oral contraceptive on tests of thyroid function. Fertil Steril 20:335-339.
29. Bounds W, Szarewski A, Lowe D, Guillebaud J. 1993. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol 48:123-125.
30. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. 1996. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174:85-92.
31. Johansson EDB, Sitruk-Ware R. 2004. New delivery systems in contraception: Vaginal rings. Am J Obstet Gynecol 190:S54-S59.
32. Szycher M. 1988. Biostability of polyurethane elastomers: A critical review. J Biomater Appl 3:297-402.
33. Szycher M, Reed AM. 1996. Medical-grade polyurethanes: A critical review. Annual Technical Conference - Society of Plastics Engineers 54th (Vol. 3) 2758-2766.
34. Deanin RD. 1991. Structure-property relations in polyurethanes. In: Szycher M, editor. High Perform Biomater. Lancaster: Technomic. p 51-69.
35. Yui N, Kataoka K, Yamada A, Sakurai Y, Sanui K, Ogata N. 1986. Drug release from monolithic devices of segmented polyether-poly(urethane urea)s having both hydrophobic and hydrophilic soft segments. Makromolekulare Chemie, Rapid Communications 7:747-750.
36. Touitou E, Friedman D. 1984. The release mechanism of drugs from polyurethane transdermal delivery systems. Int J Pharm 19:323-332.
37. Sreenivasan K. 2001. Effect of blending methyl b-cyclodextrin on the release of hydrophobic hydrocortisone into water from polyurethane. J Appl Polym Sci 81:520-522.
38. Chaudhuri B, Chang Y, Karara AH. 1988. Polyether polyurethane delivery systems. I. Evaluation of monolithic systems for N6-(D2-isopentenyl)adenosine. Int J Pharm 42:117-122.
39. Pulat M, Ekmekci A, Aslim B. 2006. The release of bovine serum albumin from polyurethane based hydrophilic and hydrophobic disks and microbiological interactions. Biomed Mater Eng 16:147-156.
40. Stokes K, McVenes R, Anderson JM. 1995. Polyurethane elastomer biostability. J Biomater Appl 9:321-354.
41. Tang L, Khan SU, Muhammad NA. 2001. Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. Pharm Dev Technol 6:531-540.
42. Ferreira H, Lucio M, de Castro B, Gameiro P, Lima JLFC, Reis S. 2003. Partition and location of nimesulide in EPC liposomes: a spectrophotometric and fluorescence study. Analytical and Bioanalytical Chemistry 377:293-298.
43. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, Hu LR. 1991. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1061:297-303.
44. van Laarhoven JA, Kruft MA, Vromans H. 2002. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm 232:163-173.
45. Markarian J. 2004. Processing and recycling advantages drive growth in thermoplastic elastomers. Plastics Additives Compound 6:22-25.
46. Yui N, Kataoka K, Sakurai y, Katono H, Sanui K, Ogata N. 1988. Novel design of microreservoir-dispersed matrixes for drug delivery formulations: Drug release from polybutadiene- and poly(ethylene oxide)-based segmented polyurethanes in relation to their microdomain structures. J Bioactive Compatible Polym 3:106-125.
47. Yui N, Kataoka K, Yamada A, Sakurai Y. 1987. Novel design of microreservoir-dispersed matrixes for drug delivery formulations: Regulative drug release from poly(ethylene oxide)- and poly(tetramethylene oxide)-based segmented polyurethanes. J Control Release 6:329-342.
48. Chien YW, Lambert HJ, Lin TK. 1975. Solution-solubility dependency of controlled release of drug from polymer matrix: Mathematical analysis. J Pharm Sci 64:1643-1647.
49. Hussain A, Ahsan F. 2005. The vagina as a route for systemic drug delivery. J Control Release 103:301-313.
50. Sueyoshi Y, Kawai K. 1932. Studies on the physicochemical properties of lecithin. J Biochem (Tokyo, Japan) 15:277-283.